Karyopharm Historical Income Statement
| KPTI Stock | USD 0.73 0.04 5.19% |
Historical analysis of Karyopharm Therapeutics income statement accounts such as Total Revenue of 153.3 M can show how well Karyopharm Therapeutics performed in making a profits. Evaluating Karyopharm Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Karyopharm Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Karyopharm Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Karyopharm Therapeutics is a good buy for the upcoming year.
Karyopharm |
About Karyopharm Income Statement Analysis
Karyopharm Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Karyopharm Therapeutics shareholders. The income statement also shows Karyopharm investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Karyopharm Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Karyopharm Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Karyopharm Therapeutics minus its cost of goods sold. It is profit before Karyopharm Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Karyopharm Therapeutics. It is also known as Karyopharm Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Karyopharm Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.As of now, Karyopharm Therapeutics' Income Tax Expense is increasing as compared to previous years. The Karyopharm Therapeutics' current Interest Income is estimated to increase to about 10.2 M, while Depreciation And Amortization is projected to decrease to under 503.5 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 206.4M | 151.9M | 141.1M | 148.1M | Total Revenue | 209.8M | 157.1M | 146.0M | 153.3M |
Karyopharm Therapeutics income statement Correlations
Click cells to compare fundamentals
Karyopharm Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Karyopharm Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 5.4M | 972K | 789K | 621K | 530K | 503.5K | |
| Interest Expense | 15.6M | 27.1M | 26.0M | 25.0M | 23.8M | 25.0M | |
| Selling General Administrative | 105.4M | 126.4M | 143.8M | 145.4M | 131.9M | 67.5M | |
| Total Revenue | 40.9M | 108.1M | 209.8M | 157.1M | 146.0M | 153.3M | |
| Gross Profit | 38.5M | 105.4M | 206.4M | 151.9M | 141.1M | 148.1M | |
| Other Operating Expenses | 230.2M | 279.9M | 308.1M | 299.3M | 275.6M | 177.9M | |
| Operating Income | (189.3M) | (171.9M) | (98.3M) | (142.2M) | (129.5M) | (136.0M) | |
| Ebit | (189.3M) | (168.8M) | (97.8M) | (139.9M) | (119.0M) | (124.9M) | |
| Research Development | 122.3M | 150.8M | 160.8M | 148.7M | 138.8M | 108.8M | |
| Ebitda | (183.9M) | (167.9M) | (97.0M) | (139.3M) | (118.4M) | (124.3M) | |
| Cost Of Revenue | 2.4M | 2.7M | 3.4M | 5.2M | 4.9M | 4.7M | |
| Total Operating Expenses | 227.8M | 277.2M | 304.7M | 294.1M | 270.6M | 176.4M | |
| Income Before Tax | (199.6M) | (196.0M) | (123.8M) | (164.9M) | (142.8M) | (149.9M) | |
| Net Income | (199.6M) | (196.3M) | (124.1M) | (165.3M) | (143.1M) | (150.3M) | |
| Total Other Income Expense Net | (10.3M) | (24.1M) | (25.5M) | (22.7M) | (13.2M) | (12.6M) | |
| Income Tax Expense | 40K | 309K | 268K | 369K | 323K | 339.2K | |
| Net Income From Continuing Ops | (199.6M) | (196.3M) | (124.1M) | (165.3M) | (139.8M) | (146.8M) | |
| Non Operating Income Net Other | 5.4M | 3.0M | 497K | 2.3M | 2.6M | 2.1M | |
| Net Income Applicable To Common Shares | (199.6M) | (196.3M) | (124.1M) | (165.3M) | (148.8M) | (156.2M) | |
| Interest Income | 5.4M | 2.8M | 582K | 2.4M | 9.8M | 10.2M | |
| Tax Provision | 40K | 309K | 268K | 369K | 266K | 203.5K | |
| Net Interest Income | (10.2M) | (24.3M) | (25.5M) | (22.6M) | (13.7M) | (14.4M) | |
| Reconciled Depreciation | 974K | 972K | 789K | 621K | 566K | 613.7K |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.